{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-258595","form_type":"8-K","ticker":null,"cik":"0001850838","company_name":"Omega Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.049978+00:00","generated_at":"2026-05-30T00:36:55.790234+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Omega Therapeutics CEO Mahesh Karande resigns; Kaan Certel appointed CEO and director","bullets":["Mahesh Karande resigned as President, CEO, and Board member effective November 14, 2024.","Kaan Certel, former Chief Business Officer, appointed President, CEO and Class I director same day.","Certel receives $520,000 base salary, 50% bonus target, and option to purchase 340,000 shares.","Karande severance includes base salary through May 25, 2025 or new employment, plus $250k transaction bonus.","Entered subleases with Flagship affiliates for ~22,350 rentable sq ft through August 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-258595","json":"https://secwatch.observer/filing/0001193125-24-258595.json","markdown":"https://secwatch.observer/filing/0001193125-24-258595.md","text":"https://secwatch.observer/filing/0001193125-24-258595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850838/000119312524258595/0001193125-24-258595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850838/000119312524258595/d736299d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:36:55.790234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d6d32c7c2","claim":"Mahesh Karande resigned as President and Chief Executive Officer at Omega Therapeutics, Inc..","evidence_excerpt":"On November 14, 2024 (the \" Transition Date \"), Mahesh Karande tendered his resignation as President and Chief Executive Officer and as a member of the Board of Directors (the \" Board \") of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312524258595/0001193125-24-258595-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"fada93b4d0","claim":"Kaan Certel was appointed as President and Chief Executive Officer at Omega Therapeutics, Inc..","evidence_excerpt":"On the Transition Date, the Board appointed Kaan Certel, Ph.D., the Company’s Chief Business Officer, to serve as the Company’s President and Chief Executive Officer and elected Dr. Certel to serve as a Class I director to fill the vacancy on the Board created by Mr. Karande’s resignation, in each case, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312524258595/0001193125-24-258595-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}